Recently, pathological prion protein PrP Sc , the putative key constituent of infectious agents causing transmissible spongiform encephalopathies (TSEs), was found in muscles of rodents experimentally infected with scrapie and in patients with Creutzfeldt-Jakob disease (CJD). For the assessment of risk scenarios originating from these findings (e.g., alimentary transmission of pathogens associated with bovine spongiform encephalopathy [BSE] 
Introduction
Transmissible spongiform encephalopathies (TSEs) such as scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in elk and deer, or CreutzfeldtJakob disease (CJD) and its variant form (vCJD) in humans are a group of fatal neurodegenerative disorders of the CNS. Apart from neuropathological features such as gliosis, neuronal cell loss, and spongiform change, these diseases are consistently characterized by the deposition in the CNS of a misfolded form of prion protein (PrP), which is known as PrP Sc (1) . According to the prion hypothesis (2) , the causative agents of TSEs (so-called "prions") are composed essentially of PrP Sc , and although the exact molecular structure of these pathogens remains elusive, there is substantial evidence that PrP Sc can be used as a reliable biochemical marker for TSE agents (3) (4) (5) (6) . PrP Sc deposition in TSEs is not necessarily confined to the CNS; it has also been observed in a variety of peripheral tissues from donors with experimental and nonexperimental TSEs (1) . Irrespective of an incidental observation in experimental caprine scrapie (7) , however, muscle tissue from TSE-affected animals or humans was essentially found to be negative for infectivity or PrP Sc in a variety of studies (6, (8) (9) (10) .
The detection of substantial amounts of PrP Sc in muscle tissue of mice and hamsters experimentally infected with scrapie (11) (12) (13) and of patients with sporadic CJD (14) , including those affected by inclusion body myositis (15) , has been reported only recently in a series of articles by different research groups. These new findings have revived concerns about the potential risks for public health emanating from possibly unrecognized reservoirs for PrP Sc and infectivity in muscles of animals and humans incubating TSEs. Particularly, the theoretical possibility of transmitting pathogens associated with BSE and CWD to humans via tainted beef and game, or that of iatrogenic dissemination of CJD or vCJD agent through contaminated surgical instruments used on muscle tissue, have gained considerable attention. While the assessment of such risk scenarios is certainly difficult, it could greatly benefit from a better knowledge of the time course of PrP Sc deposition in muscles at preclinical and clinical stages of incubation.
So far, apart from studies on the tongue of hamsters infected by intralingual injection of TSE agent (13) , findings have been reported only on PrP Sc or TSE infectivity in muscles from donors already exhibiting clinical symptoms (7, 11, 12, 14) . In this article we present data from a time-course study in hamsters fed with 263K scrapie, addressing the topical question of preclinical PrP Sc deposition in skeletal muscle.
Following up on experimental pathogenesis studies in mice (16) (17) (18) (19) and sheep (20) , the animal model used in this study has provided key observations on the spread of infection through the body (4, (21) (22) (23) (24) that have been confirmed in naturally occurring ovine scrapie (25) , field cases of BSE (26) , orally transmitted BSE in primates (27) , and orally transmitted or naturally occurring CWD (28, 29) . Additionally, more recent reports on the involvement of the sympathetic nervous system in vCJD (30) and the deposition of PrP Sc in muscles of patients with sporadic CJD (14) have shown the relevance of our hamster model for peripheral PrP Sc routing in TSE-affected humans.
Here we report that PrP Sc in muscles of hamsters perorally infected with scrapie was already detectable shortly before the onset of clinical symptoms, but that the bulk of PrP Sc accumulated only Preclinical deposition of pathological prion protein PrP Sc in muscles of hamsters orally exposed to scrapie late in clinical disease. Improved methods for paraffin-embedded tissue (PET) blotting and immunohistochemistry (IHC) provided detailed information about the intramuscular location of PrP Sc and led to new conceptual insights into the pathophysiology of peripheral PrP Sc routing.
Results

Time course of PrP Sc deposition in muscle tissue.
To assess whether, and to what extent, the biochemical marker for TSE infectivity, PrP Sc , accumulates at preclinical and clinical stages of incubation in skeletal, heart, and tongue muscles of hamsters fed with 263K scrapie, the pathological prion protein was visualized by sensitive Western blotting after extraction in the form of PrP27-30 (proteaseresistant core of the pathological prion protein PrP Sc ) from tissue samples by a high-yield purification method. PrP27-30 could not be detected in any of the examined muscle specimens or sciatic nerve samples from six hamsters sacrificed at 100 days after infection ( Figure 1A ), that is, at about 60% of the mean incubation period until terminal disease (166 ± 8 days, expressed as the mean ± SD; n = 20, with animals also taken from other experimental series). The same holds true for four out of seven animals sacrificed before the onset of scrapie symptoms at 130 days after infection ( Figure 1B ). In two of the asymptomatic animals culled at 130 days after infection, however, at least one muscle (musculus [M.] tibialis cranialis, Figure 1C , or M. masseter, not shown) was found clearly positive for PrP27-30, and in one other animal of this group PrP27-30 was detected unambiguously in four skeletal muscles (M. tibialis cranialis, M. trapezius, M. masseter, and M. psoas major) as well as in the sciatic nerve ( Figure 1D ). The signal intensities for PrP27-30 in Figure 1 , C and D, suggest that the hamster muscles found to be contaminated at 130 days after infection contained a considerably smaller amount -for most specimens possibly at least fivefold to tenfold -of PrP Sc than their counterparts taken from terminally ill donors ( Figure 1F ). The various findings regarding the presence of PrP Sc in muscles of different animals at 130 days after infection probably reflect individual variation in the progress of infection. This phenomenon, which leads to different incubation times until terminal disease, is mirrored by the extent of cerebral PrP Sc accumulation. Animals in which all muscles were found negative for PrP Sc at 130 days after infection ( Figure 1B Figures 1D and 2B) .
At the onset of clinical symptoms the observed pattern of PrP Sc deposition in muscles became more uniform. Here, the tongue samples (and sciatic nerve specimens) from all examined animals displayed strong signals for PrP27-30 ( Figure 1E , lanes T and SN) with an intensity already comparable to that observed in terminal disease ( Figure 1F, lanes T and SN) . Of the other analyzed muscles from animals at the early clinical stage of scrapie, at least two, and frequently three or four (mostly including the M. tibialis cranialis and the M. trapezius), were found to be positive for PrP27-30 (a representative example is given in Figure 1E , lanes M1-M7). These muscle specimens, however, consistently exhibited signal intensities that were still substantially lower than those observed for the corresponding muscles in terminally ill scrapie hamsters ( Figure 1F , lanes M1-M7).
At the terminal stage of scrapie all of the examined skeletal muscles and tongue specimens showed a consistent accumulation of PrP Sc as demonstrated by strong PrP27-30 immunostaining in the Western blot. Heart muscle was only very slightly positive in two out of six terminally ill animals (the sample displayed in Figure  1F , lane H, exhibits no signal for PrP27-30). Muscle samples from mock-challenged age-matched control hamsters consistently gave negative results ( Figure 1F , lane 3, shows one representative sample: M. extensor carpi radialis). Detection thresholds for PrP Sc / PrP27-30 in the Western blot analyses were in the range previously reported (12) as validated in this study by positive controls of muscle tissue from uninfected hamsters spiked with either 5 × 10 -6 g, 1 × 10 -5 g, or 2 × 10 -5 g of homogenized scrapie-infected hamster brain from terminally ill donors ( Figure 1 , A-F, lane 2).
As far as the blotting results shown in Figure 1 allow a comparison of the glycosylation and electrophoretic migration patterns of PrP27-30 from muscles, sciatic nerve, and brain, no significant differences can be discerned despite the divergent nature of these tissues. Our Western blot experiments, however, were primarily designed for the sensitive detection of pathological prion protein. A thorough molecular characterization of muscle-associated PrP Sc , which needs to be performed in future studies, will require the Western blot collation of carefully adjusted amounts of PrP27-30 that produce optimized staining intensities and clearly visible unglycosylated bands.
Intramuscular location of PrP Sc . The morphological PET blot analysis of the distribution of proteinase K-resistant PrP in muscle tissues revealed the deposition of PrP Sc in muscle fibers ( Figure  3 , A, D, and E; arrowheads) and nerve fascicles ( Figure 3 , A and E; arrows). In nerve fascicles, which consistently appeared somewhat less-intensely stained than muscle fibers, the deposition was endoneural (inset in Figure 3E ). In muscle fascicles, PrP Sc was found in adjacent, as well as topologically distant, muscle fibers (prominent in Figure 3D ; arrowheads), similar to a distribution that would be expected for motor units innervated by individual motor neurons in the spinal cord (31, 32) . Within individual muscle fibers, PrP Sc was found predominantly subsarcolemmal in the region of the fiber surface but also granularly scattered ( Figure  3D ). In some fibers PrP Sc seems to be associated with structures reminiscent of neuromuscular junctions as exemplarily indicated by the strong staining at the right border of the myofiber marked by an asterisk ( Figure 3A and inset) .
To corroborate these PET blot findings, we tried to visualize PrP Sc deposition in muscles by IHC. To reliably avoid misleading IHC immunostaining in muscle samples, a specifically designed protocol needed to be established that included pretreatment of specimens by hyaluronidase and proteinase K. The immunohistochemical examinations confirmed the subsarcolemmal location of PrP Sc as well as the protein's granularly scattered occurrence within muscle fibers ( Figure 3F and inset) . Because of the lower sensitivity of IHC as compared with PET blotting and other technical difficulties, however, immunohistochemical detection of PrP Sc could be achieved only in a small proportion of the analyzed samples ( Figure 3F ). In the majority of specimens found to be positive by PET blotting, IHC produced negative results (Figure 3C ). Muscle samples from mock-challenged control hamsters consistently gave negative PET blot and IHC results (not shown).
Infectivity in muscle tissue. To formally verify that PrP Sc found in the muscles of our model animals correlates with TSE infectivity, we performed a supplementary series of bioassays in which hamsters were intracerebrally challenged with homogenized muscle tissue from terminally ill scrapie hamsters. Four different skeletal The results of the infectivity bioassay are summarized in Table  1 . Mortalities and incubation times for the recipients in the bioassay demonstrated a consistent presence of infectivity in the range of about 2 × 10 3 to 10 × 10 3 50% intracerebral lethal doses (LD 50ic ) per gram of tissue, except for the M. triceps brachii from the forelimb, which exhibited a surprisingly low infectivity titer of only 100-300 LD 50ic /g. Three hamsters inoculated with tissue from this muscle failed to exhibit clinical symptoms until 350 days after infection. Consistent with the low amount of infectivity revealed by bioassay for the inocula of M. triceps brachii, however, the inconspicuous reporter animals were subclinically infected as shown in Figure 4 , lane 2.
The lingual muscle showed the highest infectivity titer of the examined specimens, a finding consistently mirrored by the Western blot results. The determined infectivity titers appear somewhat below the level expected on the basis of the observed PrP Sc immunostaining intensities, however. The detected amount of PrP27-30 in the muscles from terminally ill hamsters is comparable to, or even higher than, that present in 5 × 10 -6 g of homogenized scrapie-infected hamster brain ( Figure 1F , lanes M1-M7 and T versus lane 2). As previously discussed elsewhere (12) , this would correspond to an infectivity titer of approximately 10 5 LD 50ic /g if PrP Sc in muscles correlated with infectivity at a ratio similar to that observed in the brain or spinal cord of 263K-infected hamsters. Thus, the bioassay findings possibly provide an underestimation of the infectivity in muscles since the titrated inocula, after digestion of samples in collagenase A, had been heated for technical reasons (see Methods) to 80°C before intracerebral administration. Theoretically, it appears conceivable that this treatment, which somewhat differs from conventional ways of tissue homogenization (11), may have partially inactivated the infectious scrapie agent originally present in situ. Comprehensive inactivation studies, however, failed to reveal a decrease of infectivity in scrapie brain homogenate from 263K-infected hamsters heated under the conditions used in our titration experiments, that is, for 10 minutes to a temperature of 80°C (33) . In light of the pertinent report by Rohwer (33) , the sensitivity of the bioassay would appear unlikely to have been reduced -if at all -by more than 0.5 logs due to our method for the preparation of inocula. Therefore, the unexpectedly low infectivity titers found in muscle samples from our model animals may point to higher PrP Sc /infectivity ratios in the examined specimens than previously established for CNS tissue (3) (4) . This explanation would also be consistent with the astonishingly low levels of infectivity measured in the M. triceps brachii despite the substantial amounts of PrP27-30 detected in that muscle.
Discussion
Our studies demonstrate that PrP Sc can be detected in skeletal muscles of hamsters fed with scrapie before the animals show clinical signs of disease. Preclinical detection of pathological prion protein in muscle tissues was confined to relatively late stages of the asymptomatic phase of incubation, however. The bulk of muscle-associated PrP Sc accumulated during clinical disease and all examined skeletal muscles and tongue specimens from terminally ill hamsters contained substantial amounts of PrP Sc in accordance with previous observations (12) . The accumulation of PrP Sc found in the latter group of animals was accompanied by the consistent presence of at least 2 × 10 3 to 10 × 10 3 LD 50ic of scrapie agent per gram of tissue in the M. biceps femoris, M. trapezius, M. psoas major, and lingual muscle. PET blot and IHC examinations corroborated the Western blot findings in our hamsters and provided new detailed information on the distribution and location of PrP Sc in muscle tissue. Since the animal model used in this study in the past has been frequently found to exhibit key pathogenetic features of peripheral PrP Sc routing (4, 12, 21-24) in several different alimentarily acquired and naturally occurring TSEs of animals and humans (14, (25) (26) (27) (28) (29) (30) , the findings reported here may well have several relevant implications:
Pathophysiology of peripheral PrP Sc deposition in muscles. In experiments with transgenic mice exhibiting a four-to eightfold overexpression of the cellular isoform of the prion protein (PrP C ) in myofibers under the control of myocyte-specific promoters, Bosque et al. (11) showed intrinsic replication of infectivity in muscles injected with scrapie agent. Here, with the more natural route of peroral infection, we have provided direct experimental evidence for the deposition of PrP Sc in myofibers, particularly subsarcolemmally, and found that the deposition of this protein in muscles is also endoneurally associated with nerve fibers. Furthermore, the distribution patterns of PrP Sc observed in muscles conspicuously resembled those known for the innervation of motor units (31, 32) . Taken together, these findings are highly indicative of spread of infection from motor neurons in the spinal cord via axonal projections to neuromuscular junctions and on from there postsynaptically into muscle fibers. The results from the Western blot studies clearly show that PrP Sc can be detected in muscles only shortly before the onset of clinical symptoms, that is, at a time point when the CNS is already heavily loaded with PrP Sc and infectivity. This, again, would most plausibly be explained by projections of the peripheral nervous system mediating centrifugal infection of muscles from the spinal cord. Further time-course studies will be necessary, however, to validate the proposed neural spreading pathway and to elucidate, or rule out, the relevance of alternative mediators for muscle invasion such as lymph and blood or neural pathways linked with the centripetal ascension of TSE agent to the CNS. Aliquots (50 μl) of homogenized muscle samples from terminally ill hamsters orally challenged with 263K scrapie were inoculated intracerebrally into groups of two to five recipients. Mortality is shown until 349 days after infection, and the experiment was terminated at 350 days after infection.
Figure 4
Testing of bioassay reporter animals for cerebral PrP Sc deposition. Western blot detection of PrP27-30, the protease-resistant core of PrP Sc , in proteinase K-digested brain homogenates from hamsters intracerebrally inoculated with muscle samples from terminally ill donors orally challenged with 263K scrapie. Lane 1: representative finding for reporter animals that succumbed to scrapie; sample from a terminally ill hamster challenged with homogenized M. biceps femoris (hindlimb) containing 10 -6 g brain tissue. Lane 2: representative finding for reporter animals that failed to show scrapie symptoms until 350 days after infection; sample from a subclinically infected hamster challenged with homogenized M. triceps brachii (forelimb) containing 10 -3 g brain tissue.
Risks for public health and protection of consumers and patients. What conclusions regarding the risks for public health emanating from "Prions in skeletal muscle" can be drawn from the findings described in this report?
For the reasons outlined above, the experimental paradigm used in our study is likely to provide a relevant model on the issue of muscle contamination. It probably reflects a worst-case rather than a best-case scenario, however, because the levels of infectivity and PrP Sc produced in the CNS and other neural tissues of 263K scrapie-infected hamsters generally tend to be higher than in nonexperimental TSEs. Indeed, other than for caprine scrapie (7) or sporadic CJD (14) , no infectivity or PrP Sc has been detected so far in skeletal muscles of cattle with BSE (10) .
If the findings in the hamster model were confirmed, to a varying degree, in ovine scrapie, BSE, or CWD, significant deposition of PrP Sc in muscles of affected sheep, cattle, and elk or deer would be expected to occur only at relatively late stages of preclinical infection, with the bulk of muscle-associated PrP Sc accumulating during clinical disease. At those stages of incubation, however, the TSE routine tests currently in use should allow both an identification of affected animals (34) with high reliability and their safe disposal. Thus, our findings strongly support the schemes for active TSE testing of animals that have already been implemented in several countries as an efficient precautionary measure to prevent muscle tissue potentially contaminated with infectious TSE agent from entering the food chain.
In addition to recent findings in patients with sporadic CJD (14), our observations in the hamster model corroborate concerns that muscles from inconspicuous patients preclinically incubating CJD or vCJD may represent a potential risk tissue for the nosocomial transmission of human TSE agents. Epidemiological evidence substantiating this hypothetical hazard has not been reported, however, and in any case the risk can be considered as effectively addressed by comprehensive precautionary measures already implemented for infection control in nosocomial settings. Particularly, recommended procedures for the routine maintenance (cleaning, disinfection, and sterilization) of surgical instruments (35, 36) aimed at the reliable removal and inactivation of unrecognized contaminations with infectious agents are expected to substantially reduce iatrogenic risks possibly originating from TSE agents in muscles -if they are firmly observed.
Since 2002, a considerable body of new data on PrP Sc and TSE infectivity in muscles of experimentally infected rodents and patients with sporadic CJD has been compiled (11) (12) (13) (14) . It remains to be examined in future studies whether, and to what extent, these findings can be transferred to nonexperimental scrapie, BSE, and CWD, or to vCJD in humans. Special attention should be paid to food products containing ruminant or cervid tongue, given the observations reported here and elsewhere (13) . In any case, the data available so far leave no doubt that, 40 years after Pattison and Millson (7) reported finding the scrapie agent in muscle tissue of an experimentally infected goat, a topical field of TSE research has been (re)opened.
Methods
Animal inoculations and preparation of tissue samples
All animal experiments were performed in accordance with European and German legal and ethical regulations and approved by the responsible review boards and authorities. Outbred Syrian hamsters were perorally infected or mock-challenged with a single dose of homogenized 263K scrapie or normal hamster brain (corresponding to 10 mg of tissue), respectively, as previously described (4) . Scrapie-infected animals were humanely sacrificed for Western blot examinations at 100 days after infection (n = 6), at 130 days after infection (n = 7), at the onset of at least two clinical signs for scrapie, such as tremor of head or whole body, incoordination of gait, or difficulty in rising up from a supine position (n = 5: 139, 145, 145, 146, and 149 days after infection), and at the terminal stage of disease (n = 6: 161, 163, 165, 170, 171, and 173 days after infection). For PET blotting of muscle samples and infectivity bioassays, five additional hamsters in the terminal stage of scrapie were sacrificed at 171, 173 and 174 and at 163 and 168 days after infection, respectively. Control animals (mock-challenged age-matched hamsters) were sacrificed at corresponding time points. Heart muscle (apex), lingual muscle (approximately 5 mm from the tip of the tongue), sciatic nerves, and seven different skeletal muscles from the hindlimb (M. biceps femoris; M. tibialis cranialis), the forelimb (M. triceps brachii [caput laterale]; M. extensor carpi radialis), the shoulder (M. trapezius), the head (M. masseter), and the back (M. psoas major) were dissected for Western blot examinations, and visible nerve fibers were removed from the muscle specimens. All samples for Western blot analyses were cut into small pieces and stored at -80°C until examination. The mass of the muscle samples ranged from approximately 40 to approximately 100 mg, and that of the sciatic nerves from approximately 5 to approximately 10 mg. Sampling from hamsters sacrificed for PET blot analysis and infectivity bioassays was performed as described below. To avoid cross contamination, instruments used for the preparation of samples were carefully cleaned after removal and processing of each specimen.
Western blot examinations
Muscle and nerve specimens to be examined by Western blotting were processed as previously described (12) for the extraction of PrP Sc in the form of PrP27-30 (3, 37) ; the final pellets were resuspended in 15 μl of 2× sample loading buffer and heated to 100°C for 5 minutes before Western blotting using the anti-PrP mAb 3F4 (38) .
Proteinase K-digested homogenate from scrapie hamster brains, used as a PrP27-30 reference in the Western blotting analyses, was prepared as outlined previously (12, 37) .
SDS-PAGE and Western blot analyses were performed as described elsewhere (3, 37) with recently published modifications (12) . PrP signals were visualized on a X-OMAT AR (Kodak; Sigma-Aldrich, Steinheim, Germany) film. Film was exposed for 30 minutes.
PET blot examinations
PET blotting of brain samples. Brains were immediately removed from sacrificed hamsters and immersed for 48 hours in 4% phosphate-buffered formalin as described by Schulz-Schaeffer et al. (39) . After treatment with formic acid for 1 hour at room temperature, brains were placed in 4% phosphate-buffered formalin for a further 24 hours and subsequently trimmed coronally into 2-to 3-mm-thick slices. Samples were embedded in paraffin wax, and PET blotting was carried out as described (39) , with slight modifications. Six-micrometer microtome slices were mounted onto nitrocellulose membranes and dried flat at 50°C for 16 hours. After washing, sections were digested with 250 μg/ml proteinase K (Roche Molecular Biochemicals, Mannheim, Germany) in PK digestion buffer containing 10 mM Tris-HCl (pH 7.8), 100 mM NaCl, and 0.1% Brij 35 for 8 hours at 55°C. Sections were then denatured in 3 M guanidine thiocyanate and blocked with 0.2% casein before labeling with mAb 3F4.
PET blotting of muscle samples. Morphological analysis of the distribution and location of PrP Sc in muscle tissue by PET blotting was performed on lingual muscle (approximately 5 mm from the tip of the tongue) and the seven different skeletal muscles specified above. The specimens were taken from three hamsters that developed terminal symptoms of scrapie after peroral infection at 171, 173, and 174 days after infection and from corresponding mock-infected controls. Animals were transcardially perfused with periodate-lysine-paraformaldehyde (22) , and removed tissue samples were immersed additionally for 5 hours in periodatelysine-paraformaldehyde. After incubation for 8 hours at 4°C in phosphate-buffered saline, muscle samples were transferred to 70% ethanol, processed in a tissue processor, and subsequently embedded in paraffin wax. For PET blot examinations of muscle tissue (2-to 3-μm-thick sections), modifications of the original protocol (39) were necessary to remove connective tissue. After prewetting blots with TBST (10 mM Tris-HCl, pH 7.8, 100 mM NaCl, 0.05 % Tween 20) sections were digested with 1.5 mg/ml collagenase A (Roche Molecular Biochemicals) in a buffer containing 10 mM Tris-HCl, pH 7.8, 100 mM NaCl, 100 mM CaCl 2 , and 0.1% Brij 35 for 30 minutes at 60°C followed by digestion using 250 μg/ml proteinase K (Roche Molecular Biochemicals) in PK digestion buffer (see above) for 8 hours at 55°C.
Immunohistochemical examinations
Examination of the distribution and location of PrP Sc in muscle tissue by IHC was performed on 2-to 3-μm-thick sections of paraffin-embedded muscle specimens prepared as described above (see PET blot examinations). Sections were pretreated with 2 mg/ml hyaluronidase (Sigma-Aldrich) in sodium acetate buffer (pH 5.2; 21 mM acetic acid, 79 mM sodium acetate) for 30 minutes at 37°C and then exposed at the same temperature and for the same time to 50 μg/ml proteinase K in TBS (10 mM Tris HCl, 133 mM NaCl, pH 7.4) containing 2 mM CaCl 2 . After incubation with the mAb 3F4 (1:500) and secondary alkaline phosphatase-coupled goat anti-mouse Ab (1:500; Dako, Hamburg, Germany) for 90 minutes each, immunostaining was performed using new fuchsine as chromogen. Subsequently, slides were counterstained with hemalaun.
Infectivity bioassay
Infectivity titers in selected muscle specimens were assessed by an incubation time-interval assay (40, 41) . For this purpose, four different skeletal muscles (M. biceps femoris, M. triceps brachii, M. trapezius, and M. psoas major) and the tip of the tongue were removed from two terminally ill scrapie hamsters sacrificed at 163 and 168 days after infection. Tissue specimens were homogenized in a way similar to that for the Western blot examinations. After removal of visible nerve fibers, samples were washed three times in TBS and incubated in a rocking device at 37°C for 3.5 hours in TBS containing 2 mM CaCl 2 and 0.25% collagenase A (Roche Molecular Biochemicals). Collagenase A digestion was performed in a total volume of 500 μl per sample. Following ultrasonification, samples were heated to 80°C for 10 minutes in order to accomplish inactivation of the enzyme and of accidental microbial contaminations prior to intracerebral inoculation. Aliquots (50 μl) of the muscle homogenates were intracerebrally inoculated into groups of two to five recipient hamsters each, and the amount of infectivity in the samples was assayed as previously described (3-4) using the incubation times shown in Table 1 (mean error of assay ± 0.4 logs). Proteinase K-digested homogenates were prepared from the brains of all reporter animals (including those that failed to show scrapie symptoms), as described elsewhere (12, 37) , and subjected to Western blot examination for PrP Sc /PrP27-30 as outlined above. The bioassay experiment was terminated at 350 days after infection.
